Evidence map›Paper›PMID 28323273›Full record

ArticleThe American journal of gastroenterology2017

Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.

Ali Rezaie, Michelle Buresi, Anthony Lembo, Henry Lin, Richard McCallum, Satish Rao, Max Schmulson, Miguel Valdovinos, Salam Zakko, Mark Pimentel

3 registry-linked trialsAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 398 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
398citing papers in PubMed, 9 pooled it
49.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04501380 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

A Randomized Open Label Trial Evaluating the Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)

TypeinterventionalSponsorBradley ConnorRan2020 to 2022Enrolled30ConditionsSmall Intestinal Bacterial Overgrowth, Gastrointestinal Disease, Gastrointestinal InfectionArmsAEMCOLO (Rifamycin SV MMX)
NCT04754724 nacompletednot on this mapstarted 2021, after this paper: background citation

Evaluation of GIMate Handheld Hydrogen Breath Monitor for Diagnosis of Lactose Malabsorption

TypeinterventionalSponsorVivante HealthRan2021 to 2021Enrolled31ConditionsLactose IntoleranceArmsGIMate, H2 Check
NCT05579561 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Is the Vegetarian Version of Therapeutic Carbohydrate Restriction as Effective as the Omnivore Version: In the Context of Remission of Type 2 Diabetes

TypeinterventionalSponsorBloomedInRan2022 to 2023Enrolled19ConditionsDiabetes Mellitus Type 2 in Obese, Hypertension, Diabetes Mellitus Type 2 With Hyperglycemia, InflammationArmsDiet
3 · Its place in the literature

Who cites it

398 citing papers in PubMed, 9 syntheses or guidelines pooled it, 808 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Review
  19. Article
  20. Review

338 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 3 countries.

Ali RezaieGI Motility Program, Division of Gastroenterology, Department of Medicine, Cedars-Sinai, Los Angeles, California, USA.
Michelle BuresiDivision of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Anthony LemboBeth Israel Deaconess Medical Center, Department of Medicine, Boston, Massachusetts, USA.
Henry LinNew Mexico VA Health Care System, Division of Gastroenterology and Hepatology, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.
Richard McCallumDepartment of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
Satish RaoDivision of Gastroenterology and Hepatology, Department of Medicine, Augusta University, Augusta, Georgia, USA.
Max SchmulsonLaboratorio de Hígado, Páncreas y Motilidad (HIPAM)-Unit of Research in Experimental Medicine, Faculty of Medicine-Universidad Nacional Autónoma de México (UNAM), Department of Medicine, Mexico City, Mexico.
Miguel ValdovinosGI Motility and Neurogastroenteroly Unit, Department of Gastroenterology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
Salam ZakkoConnecticut Gastroenterology Institute, Department of Medicine, Bristol Hospital, Bristol, Connecticut, USA.
Mark PimentelGI Motility Program, Division of Gastroenterology, Department of Medicine, Cedars-Sinai, Los Angeles, California, USA.
Augusta University · USBeth Israel Deaconess Medical Center · USBristol Hospital · USCedars-Sinai Medical Center · USInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXMotility (United States) · USTexas Tech University · USUniversidad Nacional Autónoma de México · MXUniversity of Calgary · CAUniversity of New Mexico · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesBreath tests (BTs) are important for the diagnosis of carbohydrate maldigestion syndromes and small intestinal bacterial overgrowth (SIBO). However, standardization is lacking regarding indications for testing, test methodology and interpretation of results. A consensus meeting of experts was convened to develop guidelines for clinicians and research.

methodsPre-meeting survey questions encompassing five domains; indications, preparation, performance, interpretation of results, and knowledge gaps, were sent to 17 clinician-scientists, and 10 attended a live meeting. Using an evidence-based approach, 28 statements were finalized and voted on anonymously by a working group of specialists.

resultsConsensus was reached on 26 statements encompassing all five domains. Consensus doses for lactulose, glucose, fructose and lactose BT were 10, 75, 25 and 25 g, respectively. Glucose and lactulose BTs remain the least invasive alternatives to diagnose SIBO. BT is useful in the diagnosis of carbohydrate maldigestion, methane-associated constipation, and evaluation of bloating/gas but not in the assessment of oro-cecal transit. A rise in hydrogen of ≥20 p.p.m. by 90 min during glucose or lactulose BT for SIBO was considered positive. Methane levels ≥10 p.p.m. was considered methane-positive. SIBO should be excluded prior to BT for carbohydrate malabsorption to avoid false positives. A rise in hydrogen of ≥20 p.p.m. from baseline during BT was considered positive for maldigestion.

conclusionsBT is a useful, inexpensive, simple and safe diagnostic test in the evaluation of common gastroenterology problems. These consensus statements should help to standardize the indications, preparation, performance and interpretation of BT in clinical practice and research.

Indexed as

Blind Loop SyndromeBreath TestsConsensusFructoseGastrointestinal DiseasesGlucoseHumansHydrogenLactoseLactose IntoleranceLactuloseMethaneNorth AmericaPatient SelectionPractice Guidelines as TopicFructoseGlucoseHydrogenLactoseLactuloseMethane

Identifiers

PMID28323273
PMCPMC5418558
OpenAlexW2601950088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.